Despite compelling rates of durable clinical responses to programmed cell death-1 (PD-1) blockade, advances are needed to extend these benefits to resistant tumors. We found that tumor-bearing mice deficient in the chemokine receptor CXCR3 responded poorly to anti-PD-1 treatment. CXCR3 and its ligand CXCL9 were critical for a productive CD8+ T cell response in tumor-bearing mice treated with anti-PD-1 but were not required for the infiltration of CD8+ T cells into tumors. The anti-PD-1-induced anti-tumor response was facilitated by CXCL9 production from intratumoral CD103+ dendritic cells, suggesting that CXCR3 facilitates dendritic cell-T cell interactions within the tumor microenvironment. CXCR3 ligands in murine tumors and in plasma of melanoma patients were an indicator of clinical response to anti-PD-1, and their induction in non-responsive murine tumors promoted responsiveness to anti-PD-1. Our data suggest that the CXCR3 chemokine system is a biomarker for sensitivity to PD-1 blockade and that augmenting the intratumoral function of this chemokine system could improve clinical outcomes.
Pubmed ID: 31097342 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Global nonprofit biological resource center (BRC) and research organization that provides biological products, technical services and educational programs to private industry, government and academic organizations. Its mission is to acquire, authenticate, preserve, develop and distribute biological materials, information, technology, intellectual property and standards for the advancement and application of scientific knowledge. The primary purpose of ATCC is to use its resources and experience as a BRC to become the world leader in standard biological reference materials management, intellectual property resource management and translational research as applied to biomaterial development, standardization and certification. ATCC characterizes cell lines, bacteria, viruses, fungi and protozoa, as well as develops and evaluates assays and techniques for validating research resources and preserving and distributing biological materials to the public and private sector research communities.
View all literature mentionsCommercial supplier and developer of in vivo antibodies. Provides antibodies and antibody production services.
View all literature mentionsThis monoclonal targets CD45.2
View all literature mentionsThis monoclonal targets CD103
View all literature mentionsThis monoclonal targets CD19
View all literature mentionsThis monoclonal targets CD3epsilon
View all literature mentionsThis monoclonal targets CD28
View all literature mentionsThis monoclonal targets CD16/CD32
View all literature mentionsThis isotype control targets Trinitrophenol
View all literature mentionsThis monoclonal targets CD366
View all literature mentionsThis monoclonal targets CD183 (CXCR3)
View all literature mentionsThis monoclonal targets CD279 (PD-1)
View all literature mentionsThis monoclonal targets CD3
View all literature mentionsThis monoclonal targets CD8a
View all literature mentionsThis monoclonal targets CD28
View all literature mentionsThis monoclonal targets I-A/I-E
View all literature mentionsThis monoclonal targets F4/80
View all literature mentionsThis monoclonal targets CD11c
View all literature mentionsThis monoclonal targets CD25
View all literature mentionsThis monoclonal targets CD4
View all literature mentionsThis monoclonal targets CD19
View all literature mentionsThis monoclonal targets Ly-6G Ly-6C
View all literature mentionsThis monoclonal targets CD45.1
View all literature mentionsThis monoclonal targets T-bet
View all literature mentionsThis monoclonal targets CD11c
View all literature mentionsThis monoclonal targets CD8a
View all literature mentionsThis monoclonal targets NK-1.1
View all literature mentionsThis monoclonal targets CD278
View all literature mentionsThis monoclonal targets CD39
View all literature mentionsThis monoclonal targets TCF7
View all literature mentionsThis monoclonal targets TIGIT
View all literature mentionsThis monoclonal targets CD366
View all literature mentionsThis monoclonal targets CD279
View all literature mentionsThis monoclonal targets CD137
View all literature mentionsThis monoclonal targets TNF alpha
View all literature mentionsThis monoclonal targets CD28
View all literature mentionsThis monoclonal targets Granzyme B
View all literature mentionsThis monoclonal targets CD223
View all literature mentionsThis monoclonal targets CD366
View all literature mentionsThis monoclonal targets CD11b
View all literature mentionsThis monoclonal targets CD279
View all literature mentionsThis monoclonal targets CD44
View all literature mentionsThis monoclonal targets Granzyme B
View all literature mentionsThis monoclonal targets IFN-gamma
View all literature mentionsThis monoclonal targets TNF alpha
View all literature mentionsThis monoclonal targets CD3epsilon
View all literature mentionsThis monoclonal targets CD3
View all literature mentionsThis monoclonal targets CD3
View all literature mentionsThis monoclonal targets CD8a
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis monoclonal targets CD3
View all literature mentions